Patent application number | Description | Published |
20090252689 | Hair styling composition - There is provided a hair styling composition comprising
| 10-08-2009 |
20100081729 | Microbiocidal coatings - There is provided a coating composition comprising
| 04-01-2010 |
20120016055 | MICROBIOCIDAL COATINGS - There is provided a coating composition comprising
| 01-19-2012 |
20120027711 | FIXATIVE POLYMER COMPATIABLE WITH HAIR STYLING COMPOSITION - A polymer with good compatibility comprising one or more non-ionic water soluble monomers, such as poly(ethylene glycol)(meth)acrylate (PEGMA), is provided that is suitable for use in aerosol hair styling formulations which have improved clarity. There is also provided a hair styling composition comprising (a) one or more fully soluble polymer, and (b) a solvent mixture, and optional other ingredients. | 02-02-2012 |
20120240953 | HAIR STYLING COMPOSITION - A method for styling hair comprising the steps of placing said hair in a desired configuration and applying a composition to said hair, said composition comprising
| 09-27-2012 |
20130259812 | CATIONIC POLYMER LATEXES AND USES - Described are novel polymers and home and personal care compositions incorporating said polymers. | 10-03-2013 |
20140271752 | ENCAPSULATION OF PERSONAL CARE ACTIVES - Described are methods for encapsulating a personal care active, comprising preparing an aqueous phase, comprising partially hydrolyzed polyvinyl alcohol and a cosmetically acceptable non-ionic surfactant, preparing an oil phase, comprising the personal care active and isocyanate or polyisocyanate, homogenizing the aqueous phase and oil phase to form an emulsion with particles less than one micron, and forming a dispersion of polyurea core-shell particles containing the personal care active by contacting the emulsion with an aqueous amine solution. | 09-18-2014 |
20140348937 | MICROCAPSULES - A composition is provided, comprising microcapsules, wherein said microcapsules comprise a core and an outer shell, wherein said core comprises one or more water-insoluble compound having melting point above 15° C., wherein said outer shell comprises one or more amino resin that is a reaction product of reactants comprising one or more polyamine and formaldehyde, and wherein said composition further comprises one or more formaldehyde scavenger, one or more reaction product of said amino resin with a formaldehyde scavenger, or a mixture thereof. Also provided is a method of making such a composition. | 11-27-2014 |
20140363385 | WATER RESISTANT PERSONAL CARE POLYMERS - Described are personal care compositions comprising a polymer comprising: (a) one or more polymer comprising, as polymerized units, (i) 75% to 35% by weight, based on the weight of said polymer, one or more (meth)acrylate monomer selected from at least one of C1-C4 (meth) acrylate, (meth)acrylic acid, styrene, or substituted styrene, and (ii) 25% to 65% by weight, based on the weight of said polymer, one or more hydrophobic monomer, including hydrophobically substituted (meth)acrylate monomers, with alkyl chain length from C8 to C22 and, (iii) optionally crosslinker, and, (b) at least one suncare active. Optionally, the polymer further includes a stage 2 polymer comprising, as polymerized units, (i) 10-99% of one or more monomer which has a Tg of more than 80° C. after polymer formation, (ii) 1-10% of one or more (meth)acrylate monomer containing acid functional group, and (iii) optionally, a crosslinker. | 12-11-2014 |
20150233871 | METHOD FOR MEASURING ENCAPSULATION EFFICIENCY FOR HYDROPHOBIC ACTIVES - Described are methods of determining free hydrophobic active in aqueous formulations, comprising, encapsulating a hydrophobic active, preparing a formulation comprising encapsulated hydrophobic active, adding a cyclodextrin to the formulation, thereby entraining any free hydrophobic active; and quantifying the amount of free hydrophobic active. | 08-20-2015 |
20160046747 | ALKALINE-SWELLABLE EMULSION POLYMERS - Emulsion polymer particles comprising from 25 to 45 wt % polymerized residues of at least one C | 02-18-2016 |
20160053103 | ALKALINE-SWELLABLE EMULSION POLYMERS - Emulsion polymer particles comprising from 25 to 45 wt % polymerized residues of at least one C | 02-25-2016 |
Patent application number | Description | Published |
20090162273 | Chromium oxide powder having a reduced level of hexavalent chromium and a method of making the powder - A refined chromium oxide powder having a reduced level of hexavalent chromium. The refined powder may be produced by acid and reduction washing or by heat treatment to reduce the hexavalent chromium to a biocompatible level. The powder is then packaged to limit oxidation and absorption of moisture. | 06-25-2009 |
20090324442 | Method for fabricating a biocompatible material having a high carbide phase and such material - A method of fabricating a material having a high concentration of a carbide constituent. The method may comprise adding a carbide source to a biocompatible material in which a weight of the carbide source is at least approximately 10% of the total weight, heating the carbide source and the biocompatible material to a predetermined temperature to melt the biocompatible material and allow the carbide source to go into solution to form a molten homogeneous solution, and impinging the molten homogeneous solution with a high pressure fluid to form spray atomized powder having carbide particles. The size of a particle of carbide in the atomized powder may be approximately 900 nanometers or less. The biocompatible material may be cobalt chrome, the carbide source may be graphite, and the fluid may be a gas or a liquid. | 12-31-2009 |
20120067853 | METHODS FOR MANUFACTURING POROUS ORTHOPAEDIC IMPLANTS - A method of manufacturing an orthopaedic implant device having a porous outer surface is described. In one embodiment, the implant device includes a porous layer, an intermediate layer, and a solid substrate. The porous layer is preferably bonded to the intermediate layer by cold isostatic pressing. The intermediate layer is preferably bonded by vacuum welding to the solid substrate such that the porous layer forms at least a portion of the outer surface of the orthopaedic implant device. Preferably, a diffusion bond is created between the bonded intermediate layer and the solid substrate by hot isostatic pressing. In another embodiment, a porous layer is created on an outer surface of a solid layer by selective melting. Preferably, the solid layer is bonded to the solid substrate such that the porous layer forms at least a portion of the outer surface of the orthopaedic implant device. | 03-22-2012 |
20140222158 | FEMORAL PROSTHESIS HEAD - A prosthetic head for a femoral component has a metal shell with a tapered cavity. The shell has a part-spherical outer surface defining an inner portion terminating in an open end. A polymeric material completely fills the inner portion of the hollow shell extending from an inner surface of the shell to the open end. The polymeric material includes a conically tapered socket centered about the polar axis intermediate ends of the open end wherein the shell is a hollow titanium shell having an inner surface with a porous structure for receiving a portion of the polymeric material. The hollow titanium shell inner surface has at least one rib extending inwardly toward the conically tapered socket. | 08-07-2014 |
20150068362 | METHOD FOR FABRICATING A BIOCOMPATIBLE MATERIAL HAVING A HIGH CARBIDE PHASE AND SUCH MATERIAL - A method of fabricating a material having a high concentration of a carbide constituent. The method may comprise adding a carbide source to a biocompatible material in which a weight of the carbide source is at least approximately 10% of the total weight, heating the carbide source and the biocompatible material to a predetermined temperature to melt the biocompatible material and allow the carbide source to go into solution to form a molten homogeneous solution, and impinging the molten homogeneous solution with a high pressure fluid to form spray atomized powder having carbide particles. The size of a particle of carbide in the atomized powder may be approximately 900 nanometers or less. The biocompatible material may be cobalt chrome, the carbide source may be graphite, and the fluid may be a gas or a liquid. | 03-12-2015 |
Patent application number | Description | Published |
20100057472 | METHOD AND SYSTEM FOR FREQUENCY COMPENSATION IN AN AUDIO CODEC - In a method and system for frequency compensation in an audio CODEC, a filter in a hardware audio CODEC may be configured based on power consumption and based on a frequency response of an active output device to which the filter is communicatively coupled. The filter may comprise a plurality of filter stages, which may be, for example, biquads, and the filter may be configured by enabling or disabling one or more of the stages. In this manner, power consumption of the filter may be managed by enabling and/or disabling one or more stages. Configuration of the filter may be performed dynamically depending on whether one or more audio output devices may be active. In this regard, which output device is active and its frequency response may be determined and filter coefficients may be reconfigured upon a change in which output device may be active. | 03-04-2010 |
20100204996 | METHOD AND SYSTEM FOR DYNAMIC RANGE CONTROL IN AN AUDIO PROCESSING SYSTEM - Methods and systems for dynamic range control in an audio processing system are disclosed and may include controlling a dynamic range of an audio signal by expanding the dynamic range utilizing a dynamic expander, and dividing the audio signal into a plurality of frequency bands. Each of the bands may be individually compressed utilizing a multi-band compressor. A sum of the individually compressed frequency bands may be compressed utilizing a full-band compressor. The audio signal may be filtered utilizing a pre-emphasis filter, such as an infinite impulse response filter and may be divided into frequency bands utilizing one or more finite impulse response filters and/or delay modules. The dynamic expander may include adaptive thresholds and an envelope detector. Each of the frequency bands may be compressed utilizing syllabic compression in the multi-band compressor. The compressed sum of compressed plurality of bands may be processed utilizing an audio CODEC. | 08-12-2010 |
20100303228 | METHOD AND SYSTEM FOR A DUAL ECHO CANCELLER - Methods and systems for a dual echo canceller (EC) are disclosed and may include cancelling echo in utilizing a dual echo canceller, wherein said dual echo canceller includes an active echo canceller and an adaptive echo canceller. Filter coefficients may be copied from the adaptive echo canceller to the active echo canceller for the cancellation, based on whether said adaptive echo canceller has converged. The coefficients may be copied utilizing copy logic, which may comprise divergence detection and/or echo path change detection. The coefficients may be reset to default settings utilizing the copy logic. The coefficients may be calculated utilizing normalized block least mean squares (NBLMS), and may be calculated when the NBLMS is enabled by update logic. The coefficients may be calculated utilizing linear predictive coefficient (LPC) filtered uplink and downlink signals. | 12-02-2010 |
20100304679 | Method and System For Echo Estimation and Cancellation - Methods and systems for echo estimation and cancellation are disclosed and may include estimating combined echo return loss and echo return loss enhancement (ERL+ERLE). A subband gain vector may be calculated utilizing non-linear processing, subband analysis, and the estimated ERL+ERLE to mitigate residual echo. ERL+ERLE may be estimated by averaging a difference in DL and UL signals. A maximum value of ERL+ERLE may be determined over a period of time. A non-linear distortion adjustment factor may be estimated for ERL+ERLE. An ERL+ERLE estimation error may be calibrated specific to the wireless device. The estimating of ERL+ERLE may be suspended briefly after a transition in the DL or UL signals. Comfort noise may be added to mask the residual echo, which may be mitigated following a dual echo canceller. The estimating may be suspended when the DL signal is not present. A noise level may be included in the gain calculation. | 12-02-2010 |
Patent application number | Description | Published |
20100015970 | METHOD AND SYSTEM FOR DECODING CONTROL CHANNELS USING REPETITION REDUNDANCY - Methods and systems for decoding control channels using repetition redundancy may include generating enhanced soft bits by combining soft bits generated from the two GSM SACCH blocks. Combining may comprise averaging soft bits in one GSM SACCH block and corresponding soft bits from the other GSM SACCH block. Information in one GSM SACCH block may be repeated in the other GSM SACCH block. If repetition is detected, the enhanced soft bits may comprise enhanced soft bits for at least a portion of level 1 region and level 3 region of the GSM SACCH block. Otherwise, the generated enhanced soft bits may comprise enhanced soft bits for at least a portion of level 3 region of the GSM SACCH block. | 01-21-2010 |
20120121100 | Method and Apparatus For Wind Noise Detection and Suppression Using Multiple Microphones - Unlike sound based pressure waves that go everywhere, air turbulence caused by wind is usually a fairly local event. Therefore, in a system that utilizes two or more spatially separated microphones to pick up sound signals (e.g., speech), wind noise picked up by one of the microphones often will not be picked up (or at least not to the same extent) by the other microphone(s). Embodiments of methods and apparatuses that utilize this tact and others to effectively detect and suppress wind noise using multiple microphones that are spatially separated are described. | 05-17-2012 |
20120123771 | Method and Apparatus For Wind Noise Detection and Suppression Using Multiple Microphones - Unlike sound based pressure waves that go everywhere, air turbulence caused by wind is usually a fairly local event. Therefore, in a system that utilizes two or more spatially separated microphones to pick up sound signals (e.g., speech), wind noise picked up by one of the microphones often will not be picked up (or at least not to the same extent) by the other microphone(s). Embodiments of methods and apparatuses that utilize this fact and others to effectively detect and suppress wind noise using multiple microphones that are spatially separated are described. | 05-17-2012 |
20120123772 | System and Method for Multi-Channel Noise Suppression Based on Closed-Form Solutions and Estimation of Time-Varying Complex Statistics - Multi-channel noise suppression systems and methods are described that omit the traditional delay-and-sum fixed beamformer in devices that include a primary speech microphone and at least one noise reference microphone with the desired speech being in the near-field of the device. The multi-channel noise suppression systems and methods use a blocking matrix (BM) to remove desired speech in the input speech signal received by the noise reference microphone to get a “cleaner” background noise component. Then, an adaptive noise canceler (ANC) is used to remove the background noise in the input speech signal received by the primary speech microphone based on the “cleaner” background noise component to achieve noise suppression. The filters implemented by the BM and ANC are derived using closed-form solutions that require calculation of time-varying statistics of complex frequency domain signals in the noise suppression system. | 05-17-2012 |
20120123773 | System and Method for Multi-Channel Noise Suppression - Described herein are multi-channel noise suppression systems and methods that are configured to detect and suppress wind and background noise using at least two spatially separated microphones: at least one primary speech microphone and at least one noise reference microphone. The multi-channel noise suppression systems and methods are configured, in at least one example, to first detect and suppress wind noise in the input speech signal picked up by the primary speech microphone and, potentially, the input speech signal picked up by the noise reference microphone. Following wind noise detection and suppression, the multi-channel noise suppression systems and methods are configured to perform further noise suppression in two stages: a first linear processing stage that includes a blocking matrix and an adaptive noise canceler, followed by a second non-linear processing stage. | 05-17-2012 |
20130003960 | Full Duplex Speakerphone Design Using Acoustically Compensated Speaker Distortion - A telecommunication system including a fall duplex speakerphone, comprising a first microphone to generate a coupled signal including uplink information and non-linear distortion sensed by the first microphone in a speaker phone mode, a second microphone to generate a reference signal including downlink information and the non-linear distortion sensed by the second microphone in the speaker phone mode, and an acoustic echo canceller (AEC) to receive the coupled signal from the first microphone, to receive the reference signal from the second microphone, and to cancel out the non-linear distortion included in the coupled signal based on the non-linear distortion included in the reference signal. | 01-03-2013 |
20130010906 | Method and System for Delay Locked Loop for Rake Receiver - Certain aspects of a method and system for a delay locked loop for a rake receiver are disclosed. Aspects of one method may include normalizing a signal power of a first control channel based on a threshold value. A sampling time associated with at least one or more of the following: the first control channel, a second control channel, an on-time control channel, and a data channel, may be adjusted based on a comparison between the normalized signal power of the first control channel and a signal power of the second control channel. The second control channel may be delayed with respect to the first control channel by a particular time period. The first and second control channels may be common pilot control channels (CPICHs). The combined signal power of the first control channel may be normalized based on said threshold value. | 01-10-2013 |
20130216057 | ECHO CANCELLATION USING CLOSED-FORM SOLUTIONS - A system that utilizes closed-form solutions to perform echo cancellation is described. The system includes a filter, filter parameter determination logic and a combiner. The filter is configured to process a far-end audio signal in accordance with one or more filter parameters to generate an estimated echo signal. The filter parameter determination logic is configured to update estimated statistics associated with the far-end audio signal and a microphone signal based on instantaneous statistics associated with the far-end audio signal and the microphone signal, and calculate the one or more filter parameters based upon the updated estimated statistics. The combiner is configured to generate an estimated near-end audio signal by subtracting the estimated echo signal from the microphone signal. | 08-22-2013 |
Patent application number | Description | Published |
20080261261 | System/unit and method employing a plurality of magnetoelastic sensor elements for automatically quantifying parameters of whole blood and platelet-rich plasma - A system/analyzer-unit and method/platform—using information obtained from at least one, adapted for a plurality of, magnetoelastic sensor elements in contact with one or more samples comprising blood from a patient—for automatically quantifying one or more parameters of the patient's blood. Information obtained from emissions measured from each of the sensor elements is uniquely processed to determine a quantification about the patient's blood, such as, quantifying platelet aggregation to determine platelet contribution toward clot formation; quantifying fibrin network contribution toward clot formation; quantifying platelet-fibrin clot interactions; quantifying kinetics of thrombin clot generation; quantifying platelet-fibrin clot strength; and so on. Structural aspects of the analyzer-unit include: a cartridge having at least one bay within which a sensor element is positioned; each bay in fluid communication with both (a) an entry port for injecting a first blood sample composed of blood taken from the patient (human or other mammal), and (b) a gas vent through which air displaced by injecting the first blood sample into the bay. | 10-23-2008 |
20080303673 | DYNAMIC EAS DETECTION SYSTEM AND METHOD - This invention relates to dynamically controlled, electronic article surveillance (EAS) systems whereby an array of antenna elements is digitally phased and actively driven for concurrent transmission, and digitally phased and combined in the receiver unit to improve security tag detection. In particular, the individual frequency and phase of the plurality of the transmit/receive signals are rapidly varied to allow for automated manipulation (steering) of the transmit field pattern and receive field sensitivity. It is the object of this invention to achieve the following features via means of digital phasing and dynamic computer control: sufficient far-field cancellation, null-free detection and uncompromised detection performance regardless of tag's orientation. | 12-11-2008 |
20090261976 | PHASE COUPLER FOR ROTATING FIELDS - This invention relates to dynamically controlled, electronic article surveillance (EAS) systems whereby an array of antenna elements is digitally phased and actively driven for concurrent transmission, and digitally phased and combined in the receiver unit to improve detection. In particular, the individual frequency and phase of the plurality of the transmit/receive signals are rapidly varied to allow for automated manipulation (steering) of the transmit field pattern and receive field sensitivity. The invention achieves the following features via means of digital phasing and dynamic computer control: sufficient far-field cancellation, null-free detection and uncompromised detection performance regardless of tag's orientation while using single transmission drivers to drive entire antenna structures, whether loop antenna or ferrite core antenna, using a phase coupler, thereby allowing more efficient system operation or additional features such as deactivator antenna operation. | 10-22-2009 |
Patent application number | Description | Published |
20120321553 | Ultrafiltration Concentration of Allotype Selected Antibodies for Small-Volume Administration - Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies. | 12-20-2012 |
20140178294 | Ultrafiltration Concentration of Allotype Selected Antibodies for Small-Volume Administration - Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies. | 06-26-2014 |
20140193359 | Ultrafiltration Concentration of Allotype Selected Antibodies for Small-Volume Administration - Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies. | 07-10-2014 |
20160032008 | Stable Compositions of High-Concentration Allotype-Selected Antibodies for Small-Volume Administration - Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies. | 02-04-2016 |
Patent application number | Description | Published |
20120256169 | SUBSTITUTED OLIGOAZACARBAZOLES FOR LIGHT EMITTING DIODES - Novel compounds containing substituted oligoazacarbazole chains are provided. These compounds are useful in organic light emitting devices, in particular as hosts in the emissive layer of such devices. | 10-11-2012 |
20120298966 | Host materials for oled - Novel aryl silicon and aryl germanium host materials are described. These compounds improve OLED device performance when used as hosts in the emissive layer of the OLED. | 11-29-2012 |
20130119353 | TRIPHENYLENE SILANE HOSTS - Novel aryl silicon and aryl germanium host materials, and in particular host materials containing triphenylene and pyrene fragments, are described. These compounds improve OLED device performance when used as hosts in the emissive layer of the OLED. | 05-16-2013 |
20130293094 | Asymmetric Hosts With Triaryl Silane Side Chains - Novel asymmetric host compounds containing an electron-transport moiety, a hole-transport moiety, an aromatic spacer, and a triaryl silane group are provided. These compounds are useful materials that can be incorporated into OLED devices. | 11-07-2013 |
20130306940 | HETEROLEPTIC IRIDIUM COMPLEXES CONTAINING CARBAZOLE-IMIDAZOLE-CARBENE LIGANDS AND APPLICATION OF THE SAME IN LIGHT-EMITTING DEVICES - A compound according to Formula I, as well as, devices and formulations containing the compound as described. The compound has the general formula | 11-21-2013 |
20140027733 | TRANSITION METAL COMPLEXES CONTAINING SUBSTITUTED IMIDAZOLE CARBENE AS LIGANDS AND THEIR APPLICATION IN OLEDS - Compounds having a metal M complexed to a ligand L containing a substituted imidazole carbene group, which is represented Formula (I), below: | 01-30-2014 |
20140117343 | HOST MATERIALS FOR OLEDS - Novel aryl silicon and aryl germanium host materials, and in particular host materials containing triphenylene and pyrene fragments, are described. These compounds improve OLED device performance when used as hosts in the emissive layer of the OLED. | 05-01-2014 |
20140131676 | IRIDIUM COMPLEXES WITH AZA-BENZO FUSED LIGANDS - Novel iridium complexes containing phenylpyridine and pyridyl aza-benzo fused ligands are described. These complexes are useful as light emitters when incorporated into OLEDs. | 05-15-2014 |
20140264292 | HOST COMPOUNDS FOR PHOSPHORESCENT OLEDS AND DEVICES THEREOF - A compound according to a formula I, devices incorporating the same, and formulations including the same are described. The compound according to the formula I can have the structure | 09-18-2014 |
20150014649 | Organic Light Emitting Diode Materials - The present invention relates to novel organic compounds containing a triphenylene and a carbazole. The compounds are useful for organic light-emitting diodes. The compounds are also useful for charge-transport and charge-blocking layers, and as hosts in the light-emissive layer for organic light emitting devices (OLEDs). | 01-15-2015 |
20150021557 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Compounds according to Formula I, devices containing the same and formulations containing the same are described. | 01-22-2015 |
20150053938 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A composition formed of a first mixture of a first compound and a second compound wherein the first compound has different chemical structure than the second compound; the first compound is capable of functioning as a hole transporting material in an organic light emitting device at room temperature; the first compound comprises at least one carbazole group; the first compound has a evaporation temperature T1 of 150 to 350° C.; the second compound has evaporation temperature T2 of 150 to 350° C.; the absolute value of T1−T2 is less than 20° C.; the first compound having a concentration C1 in said first mixture, and the first compound having a concentration C2 in a film formed by evaporating the first mixture in a vacuum deposition tool at a constant pressure between 1×10 | 02-26-2015 |
20150162538 | Organic Electroluminescent Materials and Devices - Novel oligocarbazole compounds containing a triphenylene and an oligocarbazole are provided. The compounds are useful in devices including organic light emitting devices (OLEDs). | 06-11-2015 |
20150179948 | Organic Electroluminescent Materials and Devices - The present invention relates to novel organic compounds containing oligocarbazoles. The compounds are useful for organic light-emitting diodes. The compounds are also useful for charge-transport and charge-blocking layers, and as hosts in the light-emissive layer for organic light emitting devices (OLEDs). | 06-25-2015 |
20150207082 | ORGANIC MATERIALS FOR OLEDS - A novel compound based on aza- and diazodibenzofurans; aza- and diaza dibenzothiophenes, such as benzothieno- and benzofuropyrimidines as well as benzothieno- and benzofuropyrazines useful for electron-transporting host material in green, red, yellow, and white phosphorescent emitting devices is disclosed. | 07-23-2015 |
20150243894 | Organic Electroluminescent Materials and Devices - The present invention relates to novel organic compounds containing oligocarbazoles. The compounds are useful for organic light-emitting diodes. The compounds are also useful for charge-transport and charge-blocking layers, and as hosts in the light-emissive layer for organic light emitting devices (OLEDs). | 08-27-2015 |
20150243903 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Novel host compounds consisting of carbazole and nitrile groups are disclosed. These compounds are useful in phosphorescent OLEDs. | 08-27-2015 |
20150243904 | Organic Electroluminescent Materials and Devices - The present invention relates to novel organic compounds comprising at least two different selections selected from the group consisting of N-phenyl carbazole, dibenzofuran, dibenzothiophene, triphenylene, aza-(N-phenyl carbazole), aza-dibenzofuran, aza-dibenzothiophene, and aza-triphenylene. The compounds are useful for organic light-emitting diodes. The compounds are also useful for charge-transport and charge-blocking layers, and as hosts in the light-emissive layer for organic light emitting devices (OLEDs). | 08-27-2015 |
20150249221 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A novel compound containing terphenylene connected to dibenzothiophene, dibenzofuran or dibenzoselenophene that can be used as hosts in phosphorescent organic light-emitting device is disclosed. | 09-03-2015 |
20150266863 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound having the structure of Formula I, A-L-B-M-D, is disclosed. In the structure of Formula I: | 09-24-2015 |
20150287933 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Novel host compounds containing indolo[3,2,1-jk]carbazole moiety are disclosed. These compounds are useful in phosphorescent OLEDs and particularly as hosts and/or electron-blocking layer materials. | 10-08-2015 |
20160028021 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A composition comprising a first compound and a second compound is described. The composition can be a mixture of a first compound having a structure according to Formula I, | 01-28-2016 |
20160093808 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A mixture containing three different compounds that is useful as a stable co-evaporation source material for a vacuum deposition tool is disclosed. The mixture comprises a first compound; a second compound; and a third compound that are all organic compounds and have different chemical structures from each other and each has an evaporation temperature T | 03-31-2016 |
20160099422 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A composition formed of a mixture of a first compound and a second compound wherein the first compound has a different chemical structure than the second compound. The first compound and the second compound are both organic compounds. At least one of the first compound and the second compound contains at least one less abundant stable isotope atom. The first compound has an evaporation temperature T | 04-07-2016 |
Patent application number | Description | Published |
20080292589 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY - The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: | 11-27-2008 |
20100098661 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS - The present invention relates to 4,5-ring annulated indole derivatives, compositions comprising at least one 4,5-ring annulated indole derivatives, and methods of using the 4,5-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. Wherein ring Z, of formula (I), is a cyclopentyl, cyclopentenyl, 5-membered heterocycloalkyl, 5-membered heterocycloalkenyl or 5-membered heteroaryl ring. | 04-22-2010 |
20110033417 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS - The present invention relates to 2,3-Substituted Indole Derivatives, compositions comprising at least one 2,3-Substituted Indole Derivative, and methods of using the 2,3-Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 02-10-2011 |
20110065651 | HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY - The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: | 03-17-2011 |
20110104109 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS - The present invention relates to Tetracyclic Indole Derivatives, compositions comprising at least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 05-05-2011 |
20110104110 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Substituted Indole Derivatives, compositions comprising at least one Substituted Indole Derivative, and methods of using these Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 05-05-2011 |
20110189127 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Tricyclic Indole Derivatives, compositions comprising at least one Tricyclic Indole Derivatives, and methods of using the Tricyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 08-04-2011 |
20110223134 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to novel Fused Tricyclic Silyl Compounds of Formula (I): | 09-15-2011 |
20120157466 | HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY - The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1 or Formula 5: | 06-21-2012 |
20120258078 | ANTIVIRAL COMPOUNDS OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C - The present invention relates to novel Linked Tricyclic Aryl Compounds, compositions comprising at least one Linked Tricyclic Compound, and methods of using Linked Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. in one aspect, the present invention provides Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein: Non-limiting examples of the Compounds of Formula (II) include compound 56 | 10-11-2012 |
20130164258 | Antiviral Compounds Composed of Three Aligned Aryl Moieties to Treat Diseases such as Hepatitis C - The present invention relates to novel Tricyclic Compounds, compositions comprising at least one Tricyclic Compound, and methods of using Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient. The present invention provides Tricyclic Compounds of Formula (I): Non-limiting examples of the Compounds of Formula (I) include compound 44 The Compounds of Formula (II) can be useful for inhibiting HCV viral replication or replicon activity, and for treating or pre-venting HCV infection in a patient. | 06-27-2013 |
20140378416 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, E, F and L are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient. | 12-25-2014 |
20150057246 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, D and R | 02-26-2015 |